

**FORM 51-102F3  
MATERIAL CHANGE REPORT**

**1. Name and Address of Company**

Nurosene Health Inc. (the “**Company**”)  
Suite 101 - 1655 Dupont Street  
Toronto, ON M6P 3T1

**2. Date of Material Change**

August 24, 2021

**3. News Release**

A press release was disseminated on August 25, 2021 via Canada Newswire.

**4. Summary of Material Change**

The Company appointed George Achilleos as Chief Operating Officer.

**5.1 Full Description of Material Change**

The Company announced that effective August 24, 2021, George Achilleos was appointed Chief Operating Officer. This is a newly established role within the Company’s leadership team and working in cooperation with the CEO, Ranj Bath, to support the execution of Nurosene’s overall strategic growth initiatives.

Mr. Achilleos brings over 25 years of experience in building and leading multi-million dollar businesses in the technology, e-Commerce and media space. He has most recently served as the President of Origin Scientific, a leader in cannabis nanotechnology solutions. In addition, George had a strong entrepreneurial background having led his own leadership consulting firm and online retailer.

Mr. Achilleos was previously a member of the Company’s advisory board before joining the team in a full-time capacity.

**5.2 Disclosure for Restructuring Transactions**

Not Applicable.

**6. Reliance on Section 7.1(2) or (3) of National Instrument 51-102**

Not Applicable.

**7. Omitted Information**

None

**8. Executive Officer**

The name of the executive officer of the Company who is knowledgeable about the material change and this report is:

Blake Sing  
Chief Financial Officer  
Email: investors@nurosene.com

9. **Date of Report**

September 1, 2021